Search
Now showing items 1-8 of 8
PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma.
(2019-11-14)
BACKGROUND:The combination of nivolumab, a programmed death-1 (PD-1) targeted monoclonal antibody, with the cytotoxic T-lymphocyte antigen-4 (CTLA-4) targeted antibody, ipilimumab, represents a new standard of care in the ...
Weighing up the pros and cons of immune checkpoint inhibitors in the treatment of melanoma.
(FUTURE MEDICINE LTD, 2016-06-01)
Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era.
(2020-08)
The potential immune intersection between COVID-19 disease and cancer therapy raises important practical clinical questions and highlights multiple scientific gaps to be filled. Among available therapeutic approaches to ...
Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists.
(BMJ PUBLISHING GROUP, 2020-01-01)
BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic has overwhelmed the health systems worldwide. Data regarding the impact of COVID-19 on cancer patients (CPs) undergoing or candidate for immune checkpoint ...
Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma.
(WILEY, 2017-04-01)
CONTEXT: Checkpoint inhibitors are emerging as important cancer therapies but are associated with a high rate of immune side effects, including endocrinopathy. OBJECTIVE: To determine the burden of thyroid dysfunction in ...
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies.
(CELL PRESS, 2018-04-09)
With the use of a mouse model expressing human Fc-gamma receptors (FcγRs), we demonstrated that antibodies with isotypes equivalent to ipilimumab and tremelimumab mediate intra-tumoral regulatory T (Treg) cell depletion ...